



| | PNOC014-01 | PNOC014-08 | PNOC014-09 | PNOC014-02 | PNOC014-03 | PNOC014-07 | PNOC014-05 | PNOC014-06 | PNOC014-04 |
|---|---|---|---|---|---|---|---|---|---|
| ※T2/Flair | -80.6% | -71.7% | -72.1% | -72.2% | -21.6% | -58.2% | 3.4% | 28.9% | 38.6% |
| ※T1 SPD | -100.0% | -100.0% | -99.5% | -93.5% | -68.5% | -34.0% | -25.6% | 58.1% | 40.3% |
| ※Total Tumor Volume | -92.1% | -91.7% | -82.1% | -72.0% | -41.7% | -53.0% | 0.4% | 16.4% | 64.4% |

Patient

FIG. 1



Growth kinetics of Target Lesions from Screening
Median time to response for MEKi
RANO PD
RANO SD
RANO PR
RANO CR
PNOC014-01
PNOC014-02
PNOC014-03
PNOC014-04
PNOC014-05
PNOC014-06
PNOC014-07
PNOC014-08
PNOC014-09
% Change from Screening
80.00
60.00
40.00
20.00
0.00
-20.00
-40.00
-60.00
-80.00
-100.00
-120.00
-500
-400
-300
-200
-100
0
100
200
300
400
500
600
700
Days from Screening Scan

FIG. 2



Clinical and radiological assessments
Clinical: Cycle 1- Day 1 & 15
Cycles 2-27, Day 1
MRI: Baseline and every 3rd cycle
End of Study (Patient #60 Cycle 27)
Enrollment/Baseline (C1D1)
Screening
Day –28 to 0
Eligibility evaluation
Study Drug Administration
C1D1 to C26D22 420 mg/m2
C27D1
Study Drug Administration
C27D1- EOS: May either continue on 420 mg/m2 or enter drug holiday any time, both at discretion of Investigator
420 mg/m2
once per week

FIG. 3